- Home
- PRQR vs SGMT Comparison
PRQR vs SGMT Comparison
Compare PRQR & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRQR | SGMT |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.3M | 164.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PRQR | SGMT |
|---|---|---|
| Price | $1.45 | $5.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $7.67 | ★ $27.00 |
| AVG Volume (30 Days) | 408.8K | ★ 830.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $1.73 |
| 52 Week High | $3.10 | $11.41 |
Technical Indicators
Market Signals| Indicator | PRQR | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 39.93 |
| Support Level | $1.33 | $5.31 |
| Resistance Level | $1.54 | $5.29 |
| Average True Range (ATR) | 0.09 | 0.51 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 31.94 | 11.62 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.